Georgia's Online Cancer Information Center

Find A Clinical Trial

Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

Status
Active
Cancer Type
Kidney Cancer
Multiple Myeloma
Trial Phase
Phase I
Eligibility
, Male and Female
Study Type
NCT ID
NCT06142396
Protocol IDs
54767414MMY2095 (primary)
Study Sponsor
Augusta University

Summary

The goal of this study is to assess the efficacy of induction treatment with daratumumab-hyaluronidase (dara SC) with cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) for four cycles in patients with newly diagnosed multiple myeloma who have new onset renal failure. This study will also investigate the difference responses in African American (AA) patients versus non-African American patients.

Objectives

The primary questions this study aims to answer are:

  1. To evaluate the very good partial response rate (VGPR) after 4 cycles of Dara-CyBord.
  2. To evaluate the renal response rate (RRR) after 4 cycles of Dara-CyBord.

Eligibility

Inclusion Criteria:

  1. Patients must have had a confirmed new diagnosis of MM following revised IMWG criteria.
  2. Patients must have Zubrod/ECOG Performance Status ≤ 2.
  3. Patients must have renal insufficiency. Renal insufficiency is defined as eCrCl < 60 mL/min (using Cockcroft-Gault Equation for Cr Cl) and/or necessitating dialysis
  4. must not have known allergies to any of the study drugs. Must have adequate organ function.
  5. International normalized ratio (INR) and prothrombin time (PT) ≤1.5 × ULN. Activated partial thromboplastin time (aPTT) ≤1.5 × ULN.

Exclusion Criteria:

  • 1. Known seropositive for: human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C.

    2. Known Chronic obstructive pulmonary disease (COPD). 3. Known Moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification.

    4. Known Clinically significant heart disease is defined as: myocardial infarction within 6 months before enrollment, or unstable or uncontrolled disease/condition related to or affection cardiac function.

    5. Women who are pregnant, breastfeeding, or planning to become pregnant while enrolled in this study.

    6. Patients with grade 3 or 4 peripheral neuropathy 7. Patients with other active malignancies that require concurrent treatment 8. Known CNS involvement or plasma cell leukemia, or AL amyloidosis 9. Participants with active infection requiring systemic therapy 10. Has known substance abuse disorders that would interfere with cooperation with the requirements of the study.

Treatment Sites in Georgia

Georgia Cancer Center at Augusta University


1411 Laney Walker Boulevard
Augusta, GA 30912
www.augusta.edu/cancer/

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.